ABUS vs INTC · P/E 5.4, rev $6.2M vs rev $52.85B
Arbutus Biopharma Corp (ABUS) versus Intel Corporation (INTC) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Intel Corporation (INTC) is a semiconductors company listed on US. It is led by Pat Gelsinger.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported INTC revenue for 2025-12-27 was $52.85B. Net income was -$267.0M. Revenue was down 0.5% from 2024-12-28 to 2025-12-27. INTC currently screens at market cap $498.43B.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. INTC currently screens at market cap $498.43B.
Not investment advice. Open the ABUS and INTC stock pages for the full models.
Not investment advice.